Compare ARMOUR Residential REIT, Inc. (ARR) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $17.09 (market cap $2.11B), while Ginkgo Bioworks Holdings Inc trades at $8.9 (market cap $593.80M). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 3.6× Ginkgo Bioworks Holdings Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 16.89% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| ARR | DNA | |
|---|---|---|
Market Cap | $2.11B | $593.80M |
Sector | Financials | Health |
52-Week High | $19.12 | $16.14 |
52-Week Low | $14.05 | $5.48 |
Dividend Yield | 16.89% | — |
Enterprise Value | — | $631.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $17.05, down 0.23% today, with a neutral technical signal and bullish moving averages. The stock shows a low P/E of 6.85 and P/B of 0.9, indicating potential undervaluation, while recent earnings beat expectations in Q1 2026. Dividend payments remain steady at $0.24 per share, supporting income appeal. Revenue for 2025 was $332M with a net income margin of 97.2%, though cash flow trends show volatility in investing activities.
Outlook is mixed: analyst consensus is a $18.50 price target with 20% buy ratings, but risks include volatile earnings and high cash flow swings. The stock offers value and yield, yet requires caution due to operational inconsistencies and market sentiment leaning hold.
DNA trades at $9.09, down 6.58% on the day, reflecting ongoing investor caution. The technical outlook is bullish based on moving averages, with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of $312.76M on $170.16M revenue in 2025, with a negative net margin of -201.05%. Recent news highlights include Ginkgo Bioworks' Q1 2026 results and its strategic pivot to autonomous laboratories following the divestiture of its biosecurity business.
The outlook remains challenging due to persistent losses and high cash burn, though the technical setup suggests potential for a near-term bounce. Investment opportunity hinges on successful execution of the new lab strategy driving future profitability. Key risks include continued negative earnings, competitive pressures in biotech, and reliance on the unproven autonomous lab model for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
